2月25日盘中,康希诺生物(06185.HK,股价37.35港元,市值92亿港元)港股股价一度大涨超15%。消息面上,公司前一日发布公告,称吸附无细胞百(组分)白破b型流感嗜血杆菌(结合)-ACYW135群脑膜炎球菌(结合)联合疫苗(DTcP-Hib-MCV4)获得药物临床试验批准。这是一款同时预防多种疾病的五联疫苗,共有三个组成部分,一是已经获批上市的亚洲首款四价流脑结合疫苗“曼海欣”、二是处于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.